{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=20", "query": { "intervention": "Part 3", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 4019, "total_pages": 402, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T17:52:54.909Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07570316", "title": "A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graves' Disease", "Graves Disease" ], "interventions": [ { "name": "Efgartigimod PH20 SC", "type": "BIOLOGICAL" }, { "name": "Placebo PH20 SC", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2026-06-10", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 29, "location_summary": "Carlsbad, California • Orange, California • Pasadena, California + 24 more", "locations": [ { "city": "Carlsbad", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07570316" }, { "nct_id": "NCT01716806", "title": "A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Disease", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "bendamustine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2012-10-31", "completion_date": "2023-09-12", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01716806" }, { "nct_id": "NCT01806064", "title": "Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "TRC105 and Axitinib", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tracon Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2013-03-08", "completion_date": "2019-06-12", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806064" }, { "nct_id": "NCT02091206", "title": "A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epilepsy", "Dravet Syndrome" ], "interventions": [ { "name": "GWP42003-P 5 mg/kg/day Dose", "type": "DRUG" }, { "name": "Placebo control", "type": "DRUG" }, { "name": "GWP42003-P 10 mg/kg/day Dose", "type": "DRUG" }, { "name": "GWP42003-P 20 mg/kg/day Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "10 Years", "sex": "ALL", "summary": "4 Years to 10 Years" }, "enrollment_count": 34, "start_date": "2014-10-22", "completion_date": "2015-03-09", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 8, "location_summary": "Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091206" }, { "nct_id": "NCT07395687", "title": "A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Overweight", "Obesity" ], "interventions": [ { "name": "UBT251", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 333, "start_date": "2026-02-02", "completion_date": "2027-02-18", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 2, "location_summary": "Cypress, California • Overland Park, Kansas", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07395687" }, { "nct_id": "NCT07213804", "title": "A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Sofetabart Mipitecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "MIRV", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1630, "start_date": "2025-10-22", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213804" }, { "nct_id": "NCT04533438", "title": "RhinAer Procedure for Treatment of Chronic Rhinitis Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Rhinitis" ], "interventions": [ { "name": "RhinAer Stylus", "type": "DEVICE" }, { "name": "Sham", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Aerin Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 116, "start_date": "2020-07-31", "completion_date": "2024-12-30", "has_results": true, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 13, "location_summary": "Roseville, California • Torrance, California • Plantation, Florida + 10 more", "locations": [ { "city": "Roseville", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04533438" }, { "nct_id": "NCT02045849", "title": "Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Bacterial" ], "interventions": [ { "name": "GSK2140944 capsule", "type": "DRUG" }, { "name": "GSK2140944 tablet", "type": "DRUG" }, { "name": "Itraconazole capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2014-01-28", "completion_date": "2014-08-21", "has_results": false, "last_update_posted_date": "2017-07-13", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02045849" }, { "nct_id": "NCT06052605", "title": "Healthy Aging in People With Epilepsy Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Healthy Aging in People with Epilepsy Program", "type": "BEHAVIORAL" }, { "name": "Patient Survey", "type": "OTHER" }, { "name": "Provider Survey", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Anny Reyes", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 380, "start_date": "2026-03-25", "completion_date": "2030-08-01", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052605" }, { "nct_id": "NCT05913505", "title": "Heart Rate Variability Biofeedback Following Traumatic Brain Injury", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Traumatic Brain Injury" ], "interventions": [ { "name": "OSC-", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Brigham Young University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 50, "start_date": "2023-02-15", "completion_date": "2024-04-24", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-11-11T17:52:54.909Z", "location_count": 1, "location_summary": "Provo, Utah", "locations": [ { "city": "Provo", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05913505" } ] }